Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vaborbactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vaborbactam SCHEMBL18967758 | 1.00 | SIGMAR1 (0.45) | SIGMAR1POLBHSD17B10HPGDALDH1A1 | |
| Vaborbactam SCHEMBL622398 | 1.00 | SIGMAR1 (0.45) | SIGMAR1POLBHSD17B10HPGDALDH1A1 | |
| Vaborbactam SCHEMBL22726486 | 1.00 | SIGMAR1 (0.45) | SIGMAR1POLBHSD17B10HPGDALDH1A1 | |
| SCHEMBL10189424 | 0.93 | POLB (0.48) | SIGMAR1POLBHSD17B10HPGDALDH1A1 | |
| SCHEMBL621552 | 0.93 | POLB (0.48) | SIGMAR1POLBHSD17B10HPGDALDH1A1 | |
| SCHEMBL10189422 | 0.93 | POLB (0.48) | SIGMAR1POLBHSD17B10HPGDALDH1A1 | |
| SCHEMBL21700157 | 0.93 | POLB (0.48) | SIGMAR1POLBHSD17B10HPGDALDH1A1 | |
| SCHEMBL10158857 | 0.90 | CYP3A4 (0.45) | SIGMAR1POLBHSD17B10HPGDALDH1A1 | |
| SCHEMBL10158855 | 0.90 | CYP3A4 (0.45) | SIGMAR1POLBHSD17B10HPGDALDH1A1 | |
| SCHEMBL22096721 | 0.89 | SIGMAR1 (0.42) | SIGMAR1POLBHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 582 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039257-B1 | PHARMACEUTICAL COMPOSITION AND KIT CONTAINING A PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM BETA-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE | FUJIFILM CORP (JP) | 2026-05-27 | — | — | EP | claimed |
| WO-2026104587-A1 | CYCLIC BORONIC ACID ESTERS USEFUL AS ADJUVANTS IN THE TREATMENT OF BACTERIAL INFECTIONS | ADJUTEC PHARMA AS (NO) | 2026-05-21 | — | — | WO | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| US-12622919-B2 | Methods for treating hypervirulent Klebsiella pneumoniae infection | CITY UNIVERSITY OF HONG KONG (CN) | 2026-05-12 | — | — | US | claimed |
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2026-04-30 | — | — | US | claimed |
| WO-2026089982-A1 | CRYSTALLINE FORMS OF A MONOBACTAM | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026089981-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOBACTAM AND A SOLUBILIZER | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260103765-A1 | METHODS AND COMPOSITIONS FOR RAPID PATHOGEN DETECTION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-04-16 | — | — | US | claimed |
| US-20260102374-A1 | METHODS OF TREATING BACTERIAL INFECTIONS | MELINTA SUBSIDIARY CORP (US) | 2026-04-16 | — | — | US | claimed |
| EP-3475441-B1 | METHODS, SYSTEMS AND/OR KITS FOR DETECTING ANTIMICROBIAL RESISTANCE IN BACTERIA | BECTON DICKINSON CO (US) | 2026-03-25 | — | — | EP | claimed |
| US-11376237-B2 | Methods of treating bacterial infections | MELINTA SUBSIDIARY CORP. (US) | 2022-07-05 | — | — | US | claimed |
| EP-4007759-A1 | BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | Ningxia Academy of Agriculture and Forestry Sciences (CN) | 2022-06-08 | — | — | EP | claimed |
| US-20220170934-A1 | ASSAYS FOR IMPROVING AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING ACCURACY | OXFORD FINANCE LLC | 2022-06-02 | — | — | US | claimed |
| US-11286512-B2 | Compositions, methods, systems and/or kits for detecting antimicrobial resistance in bacteria | BECTON, DICKINSON AND COMPANY (US) | 2022-03-29 | — | — | US | claimed |
| EP-3969461-A1 | HOMODIMERIC TOBRAMYCIN ADJUVANT REPURPOSES NOVOBIOCIN AS AN EFFECTIVE ANTIBACTERIAL AGENT AGAINST GRAM-NEGATIVE BACTERIA | University of Manitoba (CA) | 2022-03-23 | — | — | EP | claimed |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-27 | — | — | US | claimed |
| EP-3666778-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | claimed |
| EP-3666778-A1 | A CRYSTALLINE CYCLIC BORONIC ACID ESTER DERIVATIVE, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2020-06-17 | — | — | EP | claimed |
| US-9687497-B1 | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | claimed |
| US-20170173055-A1 | SALTS AND POLYMORPHS OF CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA SUBSIDIARY CORP. | 2017-06-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | AADAT, NAT1, IDO1 | SIGMAR1 2554/4885POLB 1072/4885HSD17B10 764/4885 |
| US-20260103765-A1 | METHODS AND COMPOSITIONS FOR RAPID PATHOGEN DETECTION | RPAP1, RNGTT, CLPP | SIGMAR1 3401/4885POLB 33/4885HSD17B10 3456/4885 |
| US-11376237-B2 | Methods of treating bacterial infections | BCL6B, BCL6, BCL9 | SIGMAR1 3570/4885POLB 1945/4885HSD17B10 3237/4885 |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | PCSK9, PCSK7, PCSK6 | SIGMAR1 4472/4885POLB 1446/4885HSD17B10 216/4885 |
| US-20260102374-A1 | METHODS OF TREATING BACTERIAL INFECTIONS | MYD88, MCL1, BCL6B | SIGMAR1 2404/4885POLB 3700/4885HSD17B10 4771/4885 |
| US-20170173055-A1 | SALTS AND POLYMORPHS OF CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | SLC10A2, SLC10A1, BBC3 | SIGMAR1 1421/4885POLB 2557/4885HSD17B10 1038/4885 |
| US-12622919-B2 | Methods for treating hypervirulent Klebsiella pneumoniae infection | STAT4, STAT1, PKM | SIGMAR1 1801/4885POLB 1557/4885HSD17B10 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.